EU/3/00/010: Orphan designation for the treatment of essential thrombocythaemia

Anagrelide hydrochloride

Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2016 at the end of the period of market exclusivity.

On 29 December 2000, orphan designation (EU/3/00/010) was granted by the European Commission to Shire Pharmaceutical Development Ltd, United Kingdom, for anagrelide hydrochloride for the treatment of essential thrombocythaemia.

The sponsorship was transferred to Shire Pharmaceuticals Contracts Ltd, United Kingdom, in December 2001.

Anagrelide hydrochloride has been authorised in the EU as Xagrid since 16 November 2004.

More information on Xagrid can be found in the European public assessment report (EPAR) on the Agency's website.

Key facts

Active substance
Anagrelide hydrochloride
Medicine name
Intended use
Treatment of essential thrombocythaemia
Orphan designation status
EU designation number
Date of designation
Shire Pharmaceuticals Contracts Ltd
Hampshire International Business Park
Chineham, Basingstoke
Hants RG24 8EP
United Kingdom
Telephone: +44 12 56 89 40 00
Telefax: +44 12 56 89 47 08

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating